Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
about
Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacyPhase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancerOral fluoropyrimidines among the new drugs for patients with metastatic breast cancerSystematic review of ixabepilone for treating metastatic breast cancer.ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†Fluorouracil and the new oral fluorinated pyrimidines.A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane.XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancerPhase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer.A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.Mitomycin C in combination with vinorelbine in anthracycline- and/or taxane-pretreated patients with metastatic breast cancer.Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine.A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis.Breast cancer (metastatic).Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer.Hand-foot syndrome due to capecitabine.Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancerIdentification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens.Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancerHistory of the Baylor Charles A. Sammons Cancer Center.Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxanePhase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilonePooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.Factors responsible for long-term survival in metastatic breast cancer.Anticancer drug induced palmar plantar erythrodysesthesiaStudy protocol of the B-CAST study: a multicenter, prospective cohort study investigating the tumor biomarkers in adjuvant chemotherapy for stage III colon cancerBreast cancer survival and in vitro tumor response in the extreme drug resistance assay.Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation studyCombination chemotherapy for metastatic breast cancer.Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.Efficacy of Vitamin E Treatment for Hand-Foot Syndrome in Patients Receiving CapecitabineAdjuvant chemotherapy in older women with early-stage breast cancer.Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility StudyPhase II multi-center clinical study on using S-1 to treat advanced breast cancer after resistance to anthracycline and taxane drugs in Chinese patientsNucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy.Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling.
P2860
Q28088354-D96C97F0-0534-4FE3-AD2C-A0D0EB066016Q28361226-7A1350C2-1709-4AAA-8298-7B8FD22E4180Q28366029-2E23FBAF-99BB-4668-9AF9-B6247E994A2AQ30248627-42A6E92A-5B7E-4EF1-9B9C-C326DD890F21Q30317067-1312FE25-8982-407C-90E7-5277F664168CQ32052960-E26025E7-987F-420D-BE45-EFA614B812C0Q33180637-1AC0B603-2FB7-4F05-8FA2-B6ED23A45651Q33182035-03D920A8-FC6E-4300-B6DB-BDC432DFD14BQ33370632-2C997A2F-184D-4E54-B447-830ADED4427BQ33382437-3AED51E6-8F12-4FF6-B4AE-20C77FB85BB6Q33398185-6CE1C28F-E4D2-4991-8612-46293B6501F0Q33399530-D3D6C673-AAB2-459F-B4DC-8C4660D4DAC3Q33403508-B3E2E6B7-268A-4B80-BA03-AD72E637950FQ33424774-84742AC8-EBAF-4AA1-AF38-81C15BEA0781Q33430813-8C7C8B2B-6BE4-43A8-AD46-CFCD4F834AE8Q33448016-52ADBADF-7F60-476C-9CF0-1EA7CAD5F706Q33530524-6A260921-A58A-4215-A2DB-8CFCFC01EF4AQ33607719-93C14342-14C4-45A8-B3BA-E864E715AFCCQ33631745-FFAE5565-FE31-44DD-A58D-1C4318F3ECCCQ33659628-0B1BCC80-33B3-4ED5-8606-F1F1A415D253Q33718051-A6A421BF-290A-4613-B09A-2433C41CE302Q33847848-6A191109-7301-4249-BA3D-1E2882F4A2C4Q33945412-64FD98BC-2FF7-444D-855F-DA264B43A9DBQ33990883-54E31C31-68FE-4343-A816-FACDF6AAF898Q34165276-78C9AB07-AE56-4B72-BCEB-E6E00B153DF2Q34274930-222A1441-434F-496D-87D7-E8BF9F38352AQ34458907-03180937-4E0D-4082-AB78-928575CF9BA7Q34537146-89215DBF-DD24-4D89-ABA3-4CA59CF9CCDFQ34618110-12A2AEF8-FD18-4607-92D9-B6F3F4D28621Q34636336-875B6FBF-8C56-4EBE-8357-6923B35BAFB3Q34647221-BEB9F1DB-B44C-4BE0-B12D-926F31EE0D10Q34658293-6763F73F-DC26-432B-9998-DB789EC5BAD3Q34734518-AA5DD1DB-ABD6-44B6-B315-50B74C13A349Q34743448-48124D6C-A2E0-42F4-AECD-C3B7C6665FD5Q34791173-908CB029-75CB-4620-9A9F-1ED94069A7D8Q34858284-370F1F35-18BB-4864-A575-FB94B3F90CCBQ35180995-CF628D78-6DDB-4513-BC64-B9700110EAA9Q35482173-95B46036-4E75-4A86-A73C-84692D4E1EA1Q35567292-D95F8EAE-E319-4D9A-827F-B7C196A58B21Q35585064-AC24B3B6-4A62-4912-AA60-FA89F69DAFE1
P2860
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Multicenter phase II study of ...... tory metastatic breast cancer.
@ast
Multicenter phase II study of ...... tory metastatic breast cancer.
@en
type
label
Multicenter phase II study of ...... tory metastatic breast cancer.
@ast
Multicenter phase II study of ...... tory metastatic breast cancer.
@en
prefLabel
Multicenter phase II study of ...... tory metastatic breast cancer.
@ast
Multicenter phase II study of ...... tory metastatic breast cancer.
@en
P2093
P1476
Multicenter phase II study of ...... tory metastatic breast cancer.
@en
P2093
A U Buzdar
B Osterwalder
H U Burger
P M LoRusso
P304
P356
10.1200/JCO.1999.17.2.485
P407
P577
1999-02-01T00:00:00Z